Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow InspireMD, Inc.

Get SEC filing alerts via email and in your feed for InspireMD, Inc.

NSPR

InspireMD, Inc.

About InspireMD, Inc.

InspireMD develops innovative medical devices for treating carotid artery disease and preventing stroke. Its core product, the MicroNet-covered CGuard stent platform, offers embolic protection during and after procedures. The company targets global markets with a focus on expanding adoption of its minimally invasive stenting solutions, leveraging clinical data and strategic partnerships to establish itself as a leader in neurovascular and vascular intervention.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from InspireMD, Inc.

1
1
InspireMD, Inc. InspireMD Reports 122% Revenue Growth to $3.4 Million, Faces Increased Net Loss and Operational Challenges

Via official filing (AI summary) | 30 days ago | 0 comments

2
1
InspireMD, Inc. InspireMD Reports 28.1% Revenue Growth to $8.98 Million for Fiscal Year 2025

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
InspireMD, Inc. InspireMD Reports 39.4% Revenue Growth in Q3 2025, Faces Increased Losses

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
InspireMD, Inc. InspireMD Reports Revenue Increase but Significant Rise in Net Losses for Q2 2025

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
InspireMD, Inc. InspireMD Reports Q1 2025 Financial Results with Increased Revenue but Higher Net Loss

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
InspireMD, Inc. InspireMD Reports 13% Revenue Growth to $7.0 Million, Faces Increased Net Loss

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
InspireMD, Inc. InspireMD Reports 16.3% Revenue Growth, But Continues to Post Net Losses in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments